Hyaluronan (HA) is a linear glycosaminoglycan of the vertebrate extracellular matrix (ECM) that is synthesised at the plasma membrane by the HA synthase (HAS) enzymes HAS1, 2 and 3. The regulation of HA synthesis has been implicated in a variety of ECM-mediated and pathological processes, including renal fibrosis. We have recently described the genomic structures of each of the human HAS genes. In the present study, we analysed the HAS2 promoter region. In 5'-rapid amplification of cDNA ends analysis of purified mRNA from human renal epithelial proximal tubular cells, we detected an extended sequence for HAS2 exon 1, relocating the transcription initiation site 
INTRODUCTION
The glycosaminoglycan hyaluronan (HA) 1 is a key component of the vertebrate extracellular matrix (ECM) and is involved in a wide range of cellular functions including migration, adhesion and proliferation (1) (2) (3) . HA is synthesised by the HA synthase (HAS) enzymes HAS1, HAS2 and HAS3
at the plasma membrane (4), the corresponding HAS genes mapping to discrete autosomal loci (5) (6) (7) (8) (9) .
Previous reports from this and other laboratories have demonstrated the importance of HA metabolism in clinical nephrology. End stage renal failure is most frequently characterised by progressive interstitial fibrosis and tubular atrophy (10) , and increased expression of HA in the renal corticointerstitium is associated with this progression (11, 12) . In high glucose concentrations which mimic diabetic nephropathy, renal proximal tubular epithelial cells (HPTC) synthesise high levels of HA, which is coincident with specific upregulation of transcription at the HAS2 locus (13). The human peritoneal mesothelial cells (HPMC) which line the peritoneal membrane synthesise HA as a normal constituent of peritoneal effluent, and this synthesis is upregulated during periods of peritonitis (14) . In an in vitro model of peritoneal wound healing (15), mechanical disruption of HPMC monolayers led to increased levels of HAS2 mRNA transcription together with an increase in HA synthesis (16).
We have recently described the genomic structures of the human H A S genes (17), and demonstrated that ~500 bp upstream of each HAS reference mRNA sequence showed constitutive promoter activity in a high-throughput luciferase analysis system (18,19). The sequence upstream of HAS2 was the least active in this assay, but still conformed to our criteria for promoter activity (18) . In the present study, we describe further investigation of the transcriptional regulation of the endonucleases from New England Biolabs, Hitchin, Herts, UK), cloned into a modified pGL-3 luciferase reporter vector (17) and sequenced to ensure fidelity of amplification using vector-specific primers RV (5'-CTAGCAAAATAGGCTGTCCC-3') and GL-2 (5'-CTTTATGTTTTTGGCGTCTTCC-3') according to the manufacturer's instructions. The ability of each HAS2 promoter fragment to drive transcription of the luciferase gene was tested transiently in human cell lines HEK-293t and TE-671 as described in detail elsewhere (17-19) with the following amendment to maximise luciferase output. The growth medium used was a 1:1 mixture of Dulbecco's modified eagle medium / Ham's F-12 nutrient mixture without L-glutamine (GIBCO, Invitrogen) supplemented with 20 mM HEPES and 2 mM L-glutamine (both GIBCO) together with 5 ng/ml sodium selenite, 5 mg/ml insulin, 5 mg/ml transferrin, 0.4 mg/ml hydrocortisone (all Sigma, Poole, Dorset, UK).
RT-PCR
cDNA was reverse transcribed from 1 mg of total RNA using Superscript II RNase H -reverse transcriptase (Invitrogen) and random hexamers (100 mM; Amersham Biosciences, Chalfont St Giles, Bucks, UK) as recommended by the manufacturer. RT-PCR primers were designed to amplify the extended 5'-UTR region identified in the present study. As shown in Fig. 1 , the Prom-RT-PCR-F binding site was positioned within 5'-RACE Band 2 and spanned positions 55-76 from the new TIS, amplifying 77 nucleotides of sequence upstream of the transcription start site described previously in NM_005328. Prom-RT-PCR-R primed within HAS2 exon 2.
RT-PCR was carried out from total RNA extracted from a range of human cells using TRI Reagent (Sigma) according to the manufacturer's instructions. Gene-specific PCR reactions were performed using 2 ml of RT reaction product in a total volume of 50 ml comprising 1 x PCR buffer containing 1.5 mM MgCl 2 (Applied Biosystems), 0.2 mM dNTPs (Amersham Biosciences), 2.5 U of Amplitaq Gold
Taq polymerase (Applied Biosystems) and 1 mM oligonucleotide PCR primers. A denaturation step of 94°C for 2 min was followed by 38 cycles comprising 30 s at 94°C, 65°C at 30 s and 68°C for 90 s, after which cycling was concluded with a final extension step of 15 min at 68°C. Reaction products were analysed by electrophoresis on 1.5% agarose.
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The sequences of the HAS2 RT-PCR primers used routinely in our laboratory and not given above were sense-strand H2-F primer 5'-CATAAAGAAAGCTCGCAACACG-3' (positions 1025-1046 in NM_005328) and antisense-strand oligonucleotide H2-R 5'-ACTGCTGAGGAATGAGATCCAG-3'
(1285-1306). Extended 5'-UTRs were amplified from total RNA from mouse and rat kidneys (Ambion Europe Ltd, Cambs, UK) using primers specific to the corresponding region of the mouse (NM_008216) and rat (NM_013153) HAS2 mRNAs. Where appropriate, reaction products were processed for sequencing as described above.
DNA sequence alignment and database analysis
Alignments for the genomic sequences upstream of HAS2 from human (clone RP11-3G20, 
RESULTS

Figure 2
5'-RACE analysis of the HAS2 gene using purified mRNA
Agarose gel electrophoresis resolved the 5'-RACE nested reaction products into the two principal bands shown in Fig. 2 , which were then cloned. Sequence analysis of three randomly-selected Band 1 transformants revealed that each insert terminated at a different 5' terminal nucleotide, as highlighted in Fig. 2 . The longest of these inserts extended the HAS2 5'-UTR of NM_005328 by 49
bp. Corresponding analysis of transformants from the discrete Band 2 gave a single cloned product which extended 130 bp upstream of NM_005328 (see Fig. 1 and Fig. 2 ). This has now been submitted to the EBI Data Bank with the accession number AJ604570. These results were replicated reproducibly in analysis using mRNA from HK-2, TE-671 and HEK-293t cells (data not shown). No bands corresponding to the predicted size of product from sequence NM_005328 were detected (Fig. 2) .
Figure 3
Analysis of luciferase activity of sequences upstream of NM_005328 and AJ604570
Luciferase assay data are shown in Fig. 3 . From the initial screen of the gDNA upstream of NM_005328, Fig. 3A shows that both cell lines produced a bipartite distribution, the difference between low-scoring constructs C, F1 and F2 and the high readings for F3-F10 being highly significant (p<0.001). The significance of variation of luciferase activity in promoter fragments F1
and F2 compared to C was equivocal. A marginal increase significant at the p<0.05 level in TE-671 cells contrasted with a decrease significant at p<0.01 in HEK-293t cells. With respect to TFBSs, sequence similarity was seen at the NF-kB site at approximately -150, the NF-Y / CCAAT element at -80 and the Sp1-5' site at -60. Similarity was also evident at the core motif of the Sp1-3' site at -40 in both murine sequences, the remainder of this region being absent.
In the equine orthologue, positions -8 to -51 surrounding Sp1-3' were absent. The longest available ESTs from human (CD654109), mouse (BY110777) and bovine HAS2 (AW429456) terminated upstream of their reference mRNA sequences. 
DISCUSSION
The importance of HA metabolism in a multiplicity of biological and pathological contexts is becoming increasingly evident, and an understanding of the mechanisms controlling its synthesis ever more desirable. HA has been implicated in chondrogenesis and cartilage homeostasis, embryonic development, immunomodulation, wound-healing and a variety of disease processes including arthritis, malignancies, pulmonary and vascular disease, together with other immune and inflammatory disorders (27-35). In addition, the transcriptional regulation of HAS2 has potential significance in renal fibrosis (10-12), diabetic nephropathy (13) and peritoneal inflammation (16).
We have recently described the genomic structures of the human HAS genes (17) and, in the present study, set out to investigate further the HAS2 promoter region.
Previously, we carried out 5'-RACE analysis on HAS2 from total RNA (17). In the present study, mRNA was purified from HK-2, HEK-293t and TE-671 cells and used as the template for 5'-RACE reactions. Since no products of the predicted size for NM_005328 were recovered, it appears that this database entry is 5' truncated. A significant number of similarly truncated sequences are deposited in the public databases (18), since imperfect methodologies for creating libraries have generated incomplete cDNAs (36). Each of the 5'-RACE products from Band 1 terminated at a different nucleotide approximately 50 bp upstream of NM_005328 and 80 bp downstream of the single 5'-terminus of Band 2. This suggests that Band 1 products were prematurely terminated, possibly due to strong secondary structure in the HAS2 5'-UTR, as discussed below.
We have shown a high-throughput luciferase system to be sensitive, accurate and reproducible in an analysis of a large number of human promoters including naturally occurring polymorphic promoter variants (18,19). This system was used to establish our quantitative definition of promoter activity at 10 x that of the promoterless vector control value (i.e. 10 x C; 18) and demonstrated that 500 bp of gDNA immediately upstream of the reference mRNA sequence of each HAS isoform had basal promoter activity (17). In the present study, we have used this system to analyse the ability of a number of HAS2 promoter constructs to drive luciferase transcription in a human renal (HEK-293t) and human medulloblastoma (TE-671) cell line (17-19). In addition, we have used Friedman's twoway analysis of variance test to compare the significance of variation in promoter activity with our previously established criterion of luciferase activity.
Luciferase activity data (Fig. 3A) provided highly significant evidence that promoter function was restricted to constructs F3-F10, clustered ~250 bp upstream of the 5' terminus of HAS2 reference mRNA sequence NM_005328. In TE-671 cells, these constructs also exceeded our previously stated threshold for promoter activity (18). There was suggestive evidence for a significant increase in luciferase activity of constructs F1 and F2 in TE-671 cells, but this was contradicted by a significant decrease in activity for these constructs in HEK-293t cells (Fig. 3A) and fell below our previous threshold in both cell lines. It thus appeared that the sequence directly upstream of NM_005328 was not active in our promoter assay. It was also seen that, in the absence of stimulation, basal promoter activity was approximately consistent for F3-F10. An overall decrease in activity in larger vectors is seen in Fig. 3A , but since this system was optimised for 500 bp inserts, we cannot discount the possibility that insert size might affect luciferase activity and are currently investigating this possibility. The luciferase activity of constructs immediately upstream of AJ604570
showed an incremental increase in luciferase activity, reaching a maximum at construct F3, as predicted from our previous data (see Fig. 3A ). Once again, higher relative activities were obtained RT-PCR showed that the extended HAS2 exon 1 was expressed in three human renal cell lines and total RNAs from murine kidney, as well as outside the kidney in a human lung fibroblast cell line and in primary human peritoneal mesothelial cells. RT-PCR products specific for either AJ604570, 5'-RACE Band 1, or for NM_005328 were detected throughout, thus no evidence for transcript 5' length variation was found. There is evidence for a natural antisense mRNA, synthesised from the opposite gDNA strand to HAS2 and which includes the complementary sequence to the HAS2 TIS (HASNT; APS, unpublished data). Since this is a potential confounder of molecular biological analysis of this locus, we designed primers to amplify trans-intronic, HAS2-specific RT-PCR products.
Alignment of gDNA sequences surrounding the 5' terminus of AJ604570 for human, murine and equine HAS2 loci illustrated the high similarity suggested previously (24). However, the above luciferase data did not show a large increase in activity in response to the addition of any one of these motifs and further analysis will be required to confirm the role of these or other sites within this region. The EST data suggested that 5' truncated sequences for human, mouse and bovine HAS2 orthologues were deposited in the NCBI database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide).
In summary, we have identified the TIS of the human HAS2 gene 130 bp upstream of the 5'
terminus of the reference HAS2 mRNA sequence deposited in the public databases. Expression of our extended HAS2 5'-UTR sequence in human and murine kidney, and in other human cells was detected. We suggest that, due to the high secondary structure of complex 5'-UTRs, the reference sequences for several HAS2 orthologues may also have 5' truncations, and that HAS2 may be subject to post-transcriptional regulation. Furthermore, we provide evidence for the evolutionary conservation of transcriptional regulatory elements upstream of our repositioned HAS2 TIS in human, murine and equine genomic DNAs. by guest on September 1, 2017
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